Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a multicenter, randomized, double‐blind, placebo‐controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM‐1019 in subjects with fibrosis stage 1‐3 (F1‐F3) NASH.
Epistemonikos ID: 718014969ee96144b8e57705b3d0eac0c326948e
First added on: May 21, 2024